MyOme - Employers

Elevate Your Employee Benefits with Genomic Intelligence

We help employers empower their workforce with preventive genomic screening and genetic counseling to deliver personalized, lifelong risk insights that deliver continuous healthcare savings and improve employee health through proactive care.

Your Workforce is Carrying Health Risks in Their Genome

A significant portion of disease risk can be uncovered through whole-genome analysis. Our Proactive Health tests identify personal health risks for conditions like heart disease and cancer and predict responses to certain medications. Together, these risk insights personalize preventive care, optimize medications, and help avoid downstream healthcare costs.

Genomic risk chart data
Coronary artery disease	Approximately 50 percent
Breast cancer	Approximately 50 percent
Prostate cancer	Approximately 70 percent
Type 2 diabetes	Approximately 70 percent
Employees	Approximately 95 percent

1. CAD Risk: McPherson R, et al. Circulation Research (2016). 2. Breast Cancer Risk: Sokolova, et al. Histopathology (2022). 3. Prostate Cancer Risk: NCI. Genetics of Prostate Cancer. Web. 4. T2D Risk: Bonnefond A, et al. Lancet Diabetes Endocrinol (2025). 5. PGx Likelihood: (a) Van Driest SL, et al. Clin Pharmacol Ther (2014). (b) Bush WS, et al. Clin Pharmacol Ther(2016). (c) Ji Y, et al. J Mol Diagn (2016).

Genomic Risk Insights Reduce Healthcare Spend

Avoid
Hospitalizations

Medication Response insights enable safe prescribing from the start. This type of screening is proven to reduce medication-related ER visits and inpatient stays by ~40%.¹

~40%

Reduce Cancer Treatment Costs

Single-Gene Risk insights for cancers, including breast cancer, can stimulate early screening, detection, and treatment. Treating breast cancer early can reduce treatment costs by >$500K.²

>$500K

Cut Heart Disease Spend

Polygenic Risk Scores for Coronary Artery Disease (CAD) can lead to early interventions—like statin therapy—that reduce heart event risk and avoid $40K in annual treatment costs.³

~$40K

Fragala MS, Keogh M, Goldberg SE, Lorenz RA, and Shaman JA. The Pharmacogenomics Journal. 2 Oct 2024; 24(5):30. doi: 10.1038/s41397-024-00350-1.
Reddy SR, Chung KC, Kansal AR, et al. Current Medical Research and Opinion. 2022; 38(5):791-800. doi: 10.1080/03007995.2022.2047536.
Kazi DS, Elkind MSV, Deutsch A, et al. Circulation. 23 Jul 2024; 150(4):e89-e101. doi: 10.1161/CIR.0000000000001258.

Employee Participation

44%

of employees engaged in the program within 90-days of access to MyOme testing

Disease Risk Detection

~14%

of employees tested carried at least one clinically significant, high-impact risk variant linked to a health condition

High-Risk Classification

~20%

of employees were identified as high-risk for cardiometabolic disease or cancer

*Results averaged across active employer programs.

More than 50% of cancers and up to 80% of cardiac diseases are preventable. By integrating genomics into employer health programs, we provide participants with knowledge that can save lives and significantly improve outcomes.

Patient support and privacy

We provide patients with support to fully understand their results, including access to genetic counselors for guidance on preventive strategies. We also ensure that personal data is encrypted and never shared without patient consent.

Privacy and Security

Get in touch to find the right program

We want to help find the right program for employers and their employees to benefit from MyOme's tests. Contact us to find out how MyOme can enhance your organization's health benefit offerings.